Clover Corporation Limited v Tobias

Link copied
Case Copied 24 min read

FEDERAL COURT OF AUSTRALIA

Clover Corporation Limited v Tobias [2020] FCA 1244

File number(s): VID 1265 of 2019
Judgment of: O'BRYAN J
Date of judgment: 27 August 2020
Catchwords:  PRACTICE AND PROCEDURE – application for stay of interlocutory orders pending determination of application for leave to appeal – whether sufficient reason for stay established – application dismissed
Legislation:

Federal Court of Australia Act 1976 (Cth) s 25(2)

Federal Court Rules 2011 (Cth) r 36.08, Division 7.5

Cases cited:

Alexander v Cambridge Credit Corporation Ltd (Receivers Appointed) (1985) 2 NSWLR 685

Exagym Pty Ltd v Professional Gymnasium Equipment Company Pty Ltd (No 2) [1994] 2 Qd R 129

Powerflex Services Pty Ltd v Data Access Corporation (1996) 67 FCR 65

Division: General Division
Registry: Victoria
National Practice Area: Commercial and Corporations
Sub-area: Commercial Contracts, Banking, Finance and Insurance
Number of paragraphs: 42
Date of hearing: 27 August 2020
Counsel for the Applicants: Mr I P Horak with Ms L Davis
Solicitor for the Applicants: Piper Alderman
Counsel for the Second Respondent: Mr D Savage QC with Mr B Carew
Solicitor for the Second Respondent: McKean Park

 

ORDERS

VID 1265 of 2019
BETWEEN:

CLOVER CORPORATION LIMITED ABN 85 003 622 866

First Applicant

NU-MEGA INGREDIENTS PTY LTD

Second Applicant

AND:

PETER FREDERICK TOBIAS

First Respondent

PHARMAMARK NUTRITION PTY LTD

Second Respondent

ORDER MADE BY:

O'BRYAN J

DATE OF ORDER:

27 AUGUST 2020

THE COURT ORDERS THAT:

1.For so long as the laws of the State of Victoria or procedures implemented by the Federal Court of Australia in response to the COVID-19 pandemic operate to limit or exclude the parties, their legal representatives and members of the public from being able to attend hearings at the Commonwealth Law Courts, Melbourne, the following orders apply to hearings in this proceeding:

(a)Under s 17(4) of the Federal Court of Australia Act 1976 (Cth) (Act), the public is excluded from the hearing other than by adopting the following procedure:

If a member of the public wishes to observe the hearing, they must contact the Associate to O’Bryan J on (03) 8600 3619 or by email to associate.obryanj@fedcourt.gov.au.

(b)Unless the Court otherwise orders, no person, being a member of the public, who is observing the hearing by accessing any video link, audio link or other means may:

(i)make any video or audio recording or photography of the hearing or any part of it; or

(ii)participate in or interrupt the hearing,

provided that nothing in this order shall prevent any person, based on what they have heard during the hearing:

(iii)making their own notes or record of the proceeding; or

(iv)publishing a fair report of the proceeding.

(c)The Court notes that a contravention of paragraph 1(b) of these orders may constitute a contempt of court and be punishable accordingly.

(d)Pursuant to s 47A of the Act, testimony be permitted to be given by any witness by video link, audio link or other appropriate means.

(e)Pursuant to s 47E of the Act, a person who is to…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Clover Corporation Limited v Tobias and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCA 1244
Decision Date

CaseChat Overview and Summary

Clover Corporation Limited and Clover Property Investment Group filed proceedings against Mr Tobias and Pharmamark alleging misuse of confidential information. The Court issued a search order, which resulted in the copying of numerous electronic documents from Pharmamark's computers. The Court then set up a regime to determine which of the seized electronic documents could be inspected. Pharmamark applied for a stay of the orders pending the determination of an application for leave to appeal. The court was required to decide whether there was a sufficient reason for granting the stay of the interlocutory orders. The court found that there was no proper basis for the grant of a stay and dismissed the application. The court found that Pharmamark had not established any basis for the grant of a stay of the order made on 24 June 2020 or for the two alternative orders it now seeks. The assertions that it will suffer prejudice by reason of the inspection protocol have no basis. The protocol does not permit confidential documents belonging to Pharmamark to be provided to the Clover companies. The protocol only allows the documents to be inspected by the expert. In that regard, the evidence shows that Mr Ben Gardiner, a member of the Victorian Bar and the Queensland Bar, has been appointed as the expert pursuant to the protocol and that he is an independent barrister with no connection to either party. The court rejected the submission that disclosure of the documents to Mr Gardiner, subject to the obligation of confidentiality in the protocol, will occasion any prejudice to Pharmamark. The court is also not persuaded that there is any realistic prospect of prejudice being caused if Mr Gardiner seeks assistance from the technical expert nominated in the protocol. The application for a stay and the application for alternative orders are refused. Pharmamark is to pay the applicants’ costs of, and incidental to, the interlocutory application. The costs are to be costs in proceeding VID 453 of 2020.

Orders

Orders of the court

1. For so long as the laws of the State of Victoria or procedures implemented by the Federal Court of Australia in response to the COVID-19 pandemic operate to limit or exclude the parties, their legal representatives and members of the public from being able to attend hearings at the Commonwealth Law Courts, Melbourne, the following orders apply to hearings in this proceeding:

(a) Under s 17(4) of the Federal Court of Australia Act 1976 (Cth) (Act), the public is excluded from the hearing other than by adopting the following procedure:

If a member of the public wishes to observe the hearing, they must contact the Associate to O’Bryan J on (03) 8600 3619 or by email to associate.obryanj@fedcourt.gov.au.

(b) Unless the Court otherwise orders, no person, being a member of the public, who is observing the hearing by accessing any video link, audio link or other means may:

(i) make any video or audio recording or photography of the hearing or any part of it; or

(ii) participate in or interrupt the hearing,

provided that nothing in this order shall prevent any person, based on what they have heard during the hearing:

(iii) making their own notes or record of the proceeding; or

(iv) publishing a fair report of the proceeding.

(c) The Court notes that a contravention of paragraph 1(b) of these orders may constitute a contempt of court and be punishable accordingly.

(d) Pursuant to s 47A of the Act, testimony be permitted to be given by any witness by video link, audio link or other appropriate means.

(e) Pursuant to s 47E of the Act, a person who is to give testimony pursuant to paragraph 1(d) of these orders be permitted to swear an oath or make an affirmation by video link, audio link or other appropriate means.

(f) Pursuant to s 47B of the Act, the parties be permitted to appear before the Court and to make submissions to the Court, whether in person or through a legal representative, by way of video link, audio link or other appropriate means.

(g) Pursuant to s 47D of the Act, if, in the course of examination or the appearance of a person by video link, audio link or other appropriate means, it is necessary to put a document to that person, a copy of the physical document be transmitted to the Court or that person as necessary.

2. The interlocutory application filed by the second respondent on 17 July 2020 be dismissed.

3. The second respondent pay the applicants’ costs of, and incidental to, the interlocutory application.

4. The costs referred to in order 3 be costs in proceeding VID 453 of 2020.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The grounds advanced by Pharmamark for the stay application, or the alternative orders set out above, have shifted considerably since the filing of the stay application. Even at the hearing of the application, the grounds altered. For the reasons explained below, I consider that there is no appropriate basis to grant the stay application or to make the alternative orders. Background On 21 November 2019, the Clover companies filed an originating application seeking injunctive and compensatory relief against Mr Tobias and Pharmamark in respect of alleged misuse of the Clover companies’ confidential information. By their concise statement, the Clover companies alleged that their former employee, Mr Tobias, made unauthorised copies of their confidential information shortly before he resigned and has disclosed or is threatening to disclose the confidential information to Pharmamark. The Clover companies also made an ex parte application for a search order against the respondents pursuant to Division 7.5 of the Federal Court Rules 2011 (Cth). On 21 November 2019, Wheelahan J made that order, which required the respondents to allow various representatives of the Clover companies to, amongst other things:(a)enter their premises and search for, inspect and make copies of “listed things” described in the annexure to the order; and(b)in respect of any computer to be searched, permit an independent computer expert to make a copy or digital copy of the computer hard drive and remove that copy from the premises so as to conduct a search for “listed things”. A large number of electronic documents were copied from the respondents’ computers during the execution of the search order and uploaded onto a secure database by the independent computer expert appointed for the purposes of the search order, Korda Mentha. On 6 December 2019, O’Callaghan J made orders setting up a regime to determine which of the seized electronic documents could be inspected by the Clover companies and by which Pharmamark could object to inspection. The orders provided that inspection would occur through a web portal established by Korda Mentha for that purpose. The orders then set out the following steps:(a)The Clover companies would provide Korda Mentha with a set of filtering criteria to be applied to the documents to create a subset of the documents (the initial subset).(b)Korda Mentha would give the respondents and their lawyers access to the initial subset through the web portal for a period of 10 business days for the purpose of identifying any documents in the initial subset to which they have any objection to disclosure. (c)Korda Mentha would make available to the Clover companies and their lawyers all of the documents in the initial subset to which no objection was made.(d)The respondents were then required to provide the Clover companies with an itemised list of objections on a document-by-document basis which was to include a description of the document, the objection and the basis and detailed reasons for that objection.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

For those reasons, no basis has been shown for the stay application or the alternative orders sought by Pharmamark. In those circumstances, there is no need to consider whether Pharmamark has an arguable case on the leave application.Conclusion For the foregoing reasons, the application for a stay and the application for alternative orders are refused. In relation to costs, Pharmamark sought an order that the costs of this stay application be costs in the leave application while the Clover companies sought an order that Pharmamark pay the Clover companies’ costs of and incidental to the application. I consider that the Clover companies are entitled to their costs. The stay application was a discrete application on which Pharmamark failed. Further, for the reasons given above, I consider that the arguments advanced had no proper foundation. The Clover companies also seek an order that the costs of the stay application be costs in the appeal proceeding (VID 453 of 2020). In my view, that is an appropriate order to make. Payment of those costs should not await the outcome of this proceeding (being the principal proceeding) but be made following the determination of the application for leave to appeal. If Pharmamark is successful on that application and receives an award of costs in its favour, the costs of the stay application can be offset. If Pharmamark is unsuccessful and an award of costs is made against it, both sets of costs should then be paid by it. In his submitting notice, Mr Tobias sought an opportunity to be heard on the question of costs. As no order is proposed to be made that affects Mr Tobias, I consider that it is unnecessary to afford Mr Tobias an opportunity to be heard. However, if Mr Tobias seeks such an opportunity, he has leave to make an application to vary the costs orders within 7 days.

Ratio Decidendi

Legal Principle Established

The Clover companies further submitted that:(a)the leave application has little prospect of success; and(b)the interests of justice favour the refusal of the stay - the Clover companies are entitled to the benefit of the order and it is desirable that the work of Mr Gardiner pursuant to the protocol be allowed to proceed pending the leave application so as to avoid delay in the conduct of the proceeding.Consideration The applicable principles concerning the application for a stay were not in dispute. In Powerflex Services Pty Ltd v Data Access Corporation (1996) 67 FCR 65 at 66, the Full Court agreed with the principles stated by the New South Wales Court of Appeal in Alexander v Cambridge Credit Corporation Ltd (Receivers Appointed) (1985) 2 NSWLR 685 at 694-5:(a)it is unnecessary to show “special” circumstances for the grant of a stay and it is “sufficient that the applicant for the stay demonstrates a reason or an appropriate case to warrant the exercise of discretion in his favour”;(b)a successful party is entitled to the benefit of the judgment obtained and is entitled to commence with the presumption that the judgment is correct;(c)it follows that the onus is upon the applicant for the stay to demonstrate a proper basis for a stay that will be fair to all parties;(d)the Court will weigh considerations such as the balance of convenience and the competing rights of the parties before it;(e)if an appeal will be rendered nugatory unless a stay is granted, that will be a substantial factor in favour of the grant of a stay; and(f)while the Court will not generally speculate about the appellant's prospects of success (given that argument concerning the substance of the appeal is typically and necessarily attenuated on a stay application), the Court may make some preliminary assessment about whether the appellant has an arguable appeal in order to assess the competing interests of the parties. In my view, Pharmamark has failed to establish any basis for the grant of a stay of the order made on 24 June 2020 or for the two alternative orders it now seeks. The assertions that it will suffer prejudice by reason of the inspection protocol have no basis. The protocol does not permit confidential documents belonging to Pharmamark to be provided to the Clover companies. The protocol only allows the documents to be inspected by the expert. In that regard, the protocol requires that the expert must be an experienced member of the Victorian Bar who is independent of the Clover companies and who is required to keep all information disclosed to him or her confidential. The evidence shows that Mr Ben Gardiner, a member of the Victorian Bar and the Queensland Bar, has been appointed as the expert pursuant to the protocol and that he is an independent barrister with no connection to either party. I reject the submission that disclosure of the documents to Mr Gardiner, subject to the obligation of confidentiality in the protocol, will occasion any prejudice to Pharmamark. I am also not persuaded that there is any realistic prospect of prejudice being caused if Mr Gardiner seeks assistance form the technical expert nominated in the protocol.